Interaction of combinations of drugs, chemosensitizers, and peptides with the P-glycoprotein multidrug transporter

Biochemical Pharmacology

Volumn 53, Issue 12, 1997, Pages 1789-1797

  DiDiodato, Giulio ^a   Sharom, Frances J ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Antagonism; Drag transport; Median effect analysis; Multidrug resistance; Plasma membrane vesicles; Synergism

Indexed keywords

COLCHICINE; CYCLOSPORIN A; GLYCOPROTEIN P; LEUPEPTIN; PEPSTATIN; PEPTIDE; RESERPINE; VALINOMYCIN; VERAPAMIL; VINBLASTINE;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMOSENSITIVITY; DRUG BINDING; DRUG TRANSPORT; EFFUSION; HYDROPHOBICITY; MEMBRANE VESICLE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANIMALS; CELL LINE; CELL MEMBRANE; COLCHICINE; CYCLOSPORINE; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; LEUPEPTINS; OLIGOPEPTIDES; P-GLYCOPROTEIN; PEPTIDES; RESERPINE; VALINOMYCIN; VINBLASTINE;

EID: 0030872676     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00007-5     Document Type: Article

References (36)

1. Higgins CF, ABC transporters: From microorganisms to man. Annu Rev Cell Biol 8: 67-113, 1992.
2. Doige CA and Ames GF-L, ATP-dependent transport systems in bacteria and humans: Relevance to cystic fibrosis and multidrug resistance. Annu Rev Microbiol 47: 291-319, 1993.
3. Bellamy WT, P-Glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol 36: 161-183, 1996.
4. Leveille-Webster CR and Arias IM, The biology of the P-glycoproteins. J Membr Biol 143: 89-102, 1995.
5. Gottesman MM and Pastan I, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
6. Doige CA and Sharom FJ, Transport properties of P-glycoprotein in plasma membrane vesicles from multidrug-resistant Chinese hamster ovary cells. Biochim Biophys Acta 1109: 161-171, 1992.
7. Sharom FJ, Yu X and Doige CA, Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J Biol Chem 268: 24197-24202, 1993.
8. Sharom FJ, Characterization and functional reconstitution of the multidrug transporter. J Bioenerg Biomembr 27: 15-22, 1995.
9. Sharom FJ, DiDiodato G, Yu X and Ashbourne KJD, Interaction of the P-glycoprotein multidrug transporter with peptides and ionophores. J Biol Chem 270: 10334-10341, 1995.
10. Sarkadi B, Müller M, Homolya L, Holló Z, Seprodi J, Germann UA, Gottesman MM, Price EM and Boucher RC, Interaction of bioactive hydrophobic peptides with the human multidrug transporter. FASEB J 8: 766-770, 1994.
11. Loe DW and Sharom FJ, Interaction of multidrug-resistant Chinese hamster ovary cells with the peptide ionophore gramicidin D. Biochim Biophys Acta 1190: 72-84, 1994.
12. Sharom FJ, Yu X, DiDiodato G and Chu JWK, Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport. Biochem J 320: 421-428, 1996.
13. Georges E, Sharom FJ and Ling V, Multidrug resistance and chemosensitization: Therapeutic implications for cancer chemotherapy. Adv Pharmacol 21: 185-220, 1990.
14. Ford JM and Hait WN, Pharmacologic intervention of multidrug resistance. Cytotechnology 12: 171-212, 1993.
15. Ford JM, Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitizers. Eur J Biochem 32A: 991-1001, 1996.
16. Fisher GA and Sikic BI, Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 9: 363-382, 1995.
17. Efferth T, Fabry U and Osieka R, Is there a realistic chance for clinical modulation of multidrug resistance? Onkologie 18: 258-260, 1995.
18. Germann UA and Harding MW, Chemosensitizers to overcome and prevent multidrug resistance. J Natl Cancer Inst 87: 1573-1575, 1995.
19. Sharom FJ, Yu X, Chu JWK and Doige CA, Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochem J 308: 381-390, 1995.
20. Robert J, Proposals for concomitant use of several modulators of multidrug resistance in clinics. Anticancer Res 14: 2371-2374, 1994.
21. Eron JJ, Johnson VA, Merrill DP, Chou T-C and Hirsch MS, Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycytidine in vitro. Antimicrob Agents Chemother 36: 1559-1562, 1992.
22. Kartner N, Evernden-Porelle D, Bradley G and Ling V, Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316: 820-823, 1985.
23. Doige CA and Sharorn FJ, Strategies for purification of the P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Protein Expr Purif 2: 256-265, 1991.
24. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
25. Chou T-C, Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 59: 253-276, 1976.
26. Chou T-C and Talalay P, Analysis of combined drug effects: A new look at a very old problem. Trends Pharmacol Sci 4: 450-454, 1983.
27. Chou T-C and Talalay P, Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. In: Advances in Enzyme Regulation (Ed. Weber G), Vol. 22, pp. 27-55. Pergamon Press, Oxford, 1984.
28. Boer R, Ulrich W-R, Haas S, Borchers C, Gekeler V, Boss H, Przybylski M and Schödl A, Interaction of cytostatics and chemosensitizers with the dexniguldipine binding site on P-glycoprotein. Eur J Pharmacol 295: 253-260, 1996.
29. Hu XF, Martin TJ, Bell DR, de Luise M and Zalcberg JR, Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res 50: 2953-2957, 1990.
30. Osann S, Sweet P and Slater LM, Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro. Cancer Chemother Pharmacol 30: 152-154, 1992.
31. Lehnert M, Dalton WS, Roe D, Emerson S and Salmon SE, Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 77: 348-354, 1991.
32. Ferry DR, Russell MA and Cullen MH, P-Glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is allosterically coupled to a vinca-alkaloid-selective binding site. Biochem Biophys Res Commun 188: 440-445, 1992.
33. Boer R, Dichtl M, Borchers C, Ulrich WR, Maracek JF, Prestwich GD, Glossmann H and Striessnig J, Reversible labeling of a chemosensitizer binding domain of P-glycoprotein with a novel 1,4-dihydropyridine drug transport inhibitor. Biochemistry 35: 1387-1396, 1996.
34. Ayesh S, Shao Y-M and Stein WD, Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1316: 8-18, 1996.
35. Borgnia MJ, Eytan GD and Assaraf YG, Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 6: 3163-3171, 1996.
36. Liu R and Sharom FJ, Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. Biochemistry 35: 11865-11873, 1996.